A study for effectiveness and safety of tocilizumab therapy in rheumatoid arthritis patients with renal insufficiency.
Phase 4
- Conditions
- Rheumatoid arthritis
- Registration Number
- JPRN-UMIN000014934
- Lead Sponsor
- HO Kumamoto Saishunsou National Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in CDAI values after the 24-week treatment with tocilizumab
- Secondary Outcome Measures
Name Time Method Improvement of anemia after the 24-week treatment with tocilizumab